PREGNANCY AND BREASTFEEDING SAFETY: Zoledronic acid should not be administered to pregnant women. Women of childbearing age should be advised to use a reliable method of birth control.
It is not known whether zoledronic acid is excreted in human milk. Since many drugs are excreted in human milk, and zoledronic acid binds to bone long-term, zoledronic acid should not be administered to nursing women.
- Unopened bottles should be kept at room temperature 15-30 C (59-86 F).
- Opened bottles of solution are stable for 24 hours at 2-8 C (36-46 F).
- For treatment of postmenopausal osteoporosis, a single 5 mg infusion once a year is recommended.
- For prevention of postmenopausal osteoporosis the recommended dose is 5 mg every two years.
- Paget's disease of bone is treated with a single 5 mg infusion. Patients with Paget's disease should also receive 1500 mg of elemental calcium and 800 IU vitamin D daily, especially during the two weeks after the injection of zoledronic acid.
- For prevention or treatment of steroid-induced osteoporosis, the recommended dose is 5 mg once yearly.
DRUG CLASS AND MECHANISM:
- Zoledronic acid is an injectable drug belonging to a class of drugs called bisphosphonates that strengthen bone and are used primarily to treat osteoporosis.
- Zoledronic acid also is the active drug in Zometa, which is used for treating cancer.
- The bisphosphonate class includes etidronate (Didronel), pamidronate (Aredia), risedronate (Actonel), ibandronate (Boniva), and tiludronate (Skelid).
Quick GuideOsteoporosis Pictures Slideshow: Are Your Bones at Risk?
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Need help identifying pills and medications?
Use the pill identifier tool on RxList.